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Isradipine Twice Daily Lowers Blood Pressure 
Over 24 H 
Arie J. Man in't Veld, David G. Holmes, Antonius Lasance, and Peter de Zw art 
T h e objective of th i s s tudy w a s to compare t h e ef­
fects of i s r ad ip ine a n d p lacebo on b lood p re s su re 
(BP) at t h e e n d of t h e dos ing in te rva l ( ' trough') . Fol­
l owing a t h r e e - w e e k p lacebo per iod , 187 pa t i en t s 
w h o h a d p rev ious ly s h o w n a response to t r e a tmen t 
w i t h i s r ad ip ine (based on office BP measu remen t s ) 
we re r a n d o m i z e d to doub l e -b l i nd t r ea tmen t w i t h 
2.5 m g i s r ad ip ine twice da i ly or p lacebo for six 
weeks . Four of these pa t i en t s w i t h d r e w from t h e 
s tudy d u r i n g t h e doub l e -b l i nd p h a s e because of ad­
verse even t s (one t a k i n g i s rad ip ine a n d t h r ee t a k i n g 
placebo). Blood p re s su re d u r i n g the d o u b l e - b l i n d 
s tudy w a s a l w a y s m e a s u r e d 12 h after d r u g a d m i n ­
is t ra t ion ( t rough values) . T h e ra te of no rma l i za t i on 
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[defined as diastol ic BP (DBP) < 90 m m Hg] w a s 5 2 / 
96 (54%) in t h e i s rad ip ine - t rea ted g roup compared 
w i t h 30/87 (33%) i n t h e p lacebo g roup . A fu r the r 
12/96 (12%) pa t i en t s t a k i n g i s rad ip ine s h o w e d a fall 
i n DBP of > 10 m m Hg, a l t h o u g h the i r DBP w a s st i l l 
no t < 90 m m Hg, compared w i t h 5/87 (6%) pa t i en t s 
rece iv ing p lacebo. T h i s difference was stat ist ically 
significant (P = .003). T h u s , i s r ad ip ine in a dose of 
2.5 m g twice da i ly lowers b lood p res su re over 24 h . 
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additional antihypertensive benefit was apparent with 
doses above 7.5 mg twice daily. Thus, using doses 
higher than those required to lower blood pressure 
served only to increase the frequency a n d / o r severity of 
side effects. 
Most of these results, however , were based on blood 
pressure measurements taken 4 to 6 h after drug admin­
istration (office measurements , as is the usual practice). 
Relatively few data are available from studies in which 
blood pressure was measured at the end of the 12 h 
dosing interval (trough measurements) , a l though wha t 
data there are did show that the therapeutic effect lasts 
for 12 h with isradipine at a dose of 2.5 mg twice daily. 
Because the inclusion of patients not responding to 
treatment was thought to make the evaluation of the 
duration of effect less accurate, the study was carried 
out double-blind and placebo-controlled in patients 
w h o had already shown a clinical response to 2.5 m g 
isradipine twice daily. 
PATIENTS A N D M E T H O D S 
Pat ien t Select ion The following were the criteria for 
entry into the placebo phase of the study. Patients h a d 
Isradipine is a dihydropyridine characterized as a potent inhibitor of calcium channel influx with a high specificity for vascular smooth muscle as op­posed to cardiac muscle. In anesthetized cats and 
dogs, isradipine produces vasodilatation and increased 
coronary, cerebral, and skeletal blood flows. Cardiac 
ou tpu t a n d myocardia l contractil i ty are increased 
whereas myocardial oxygen consumption is reduced. 
Isradipine has been evaluated in several randomized, 
double-blind, parallel-group trials in the treatment of 
patients with essential hypertension. These trials used 
doses of 1.25 to 10 mg twice daily. The results of these 
trials indicated that 1.25 mg twice daily is effective in 
reducing blood pressure and that a dose-response rela­
tionship applies with doses u p to 7.5 mg twice daily. N o 
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to have received treatment with 2.5 mg isradipine twice 
daily as monotherapy for at least four weeks and h a d to 
have a documented diastolic blood pressure (DBP) 
< 95 m m Hg or a reduction in DBP of at least 10 m m Hg 
during the isradipine treatment. Patients were to show 
no clinically relevant abnormal laboratory test results. 
To qualify for entry into the double-blind phase , pa­
tients were to have a resting, sitting DBP of at least 
95 m m Hg, but not > 115 m m Hg, at the end of the 
placebo phase . 
S t u d y D e s i g n A multicenter, double-blind, parallel-
group, placebo-controlled study design was used. Total 
durat ion of the study per patient was nine weeks as 
follows: weeks 1 to 3, placebo wash-out phase; weeks 4 
to 9, 2.5 mg isradipine twice daily or placebo. Patients 
whose response to isradipine had been demonstra ted in 
a preceding clinical study directly entered the placebo 
phase of the comparative study. Patients w h o h a d not 
already shown a response with 2.5 mg isradipine twice 
daily initially received placebo for two weeks to estab­
lish the diagnosis of hypertension; this was followed by 
2.5 mg isradipine twice daily for four weeks to establish 
the response to treatment before entering the placebo 
phase . 
Patients eligible for the study received one placebo 
tablet twice daily (at 9 AM and at 9 PM) for three weeks. 
If, after three weeks of placebo, the blood pressure h a d 
still not reached the level required for inclusion, the 
placebo period was extended by two weeks to a maxi­
m u m total duration of five weeks. Patients w h o con­
formed to the admission criteria at the end of the pla­
cebo phase were randomized to receive treatment with 
either 2.5 mg isradipine or placebo twice daily. This was 
given for six weeks. 
Blood Pressure M e a s u r e m e n t Sitting pulse and blood 
pressure recordings were taken after the patient had 
been in the clinic for at least 20 min and had rested in a 
sitting position for at least 3 min. Systolic blood pressure 
(SBP) was recorded with a mercury sphygmomanome­
ter at Korotkoff phase I and DBP was recorded at Korot-
koff phase V. Throughout the study, blood pressure 
measurement for each patient was performed with the 
same cuff size (appropriate to the circumference of the 
arm), from the same arm and, if possible, by the same 
investigator. 
For the examinations at the end of the placebo period 
and after four and six weeks of the double-blind treat­
ment , the patient a t tended the clinic in the morning 
be tween 8:30 and 9:30 AM, 12 h ( ± 3 0 min) after the 
previous evening medication at 9 PM. Blood pressure 
was measured (trough values), followed by administra­
tion of the morning dose of isradipine. The effect on 
blood pressure at peak was not recorded. If, on the days 
of these three visits the morning dose h a d inadvertently 
been taken before at tending the clinic, or the previous 
evening dose had been taken more than 13 or less than 
11 h before, the examination was pos tponed until the 
next day to ensure that true trough values were ob­
tained. 
Statist ical M e t h o d s The null-hypothesis to be tested 
was: there are no differences in trough blood pressure-
lowering effects between treatment with 2.5 mg isradi­
pine twice daily and placebo twice daily after six weeks 
of treatment. The Wilcoxon signed-rank test was used to 
compare the changes from baseline within each treat­
ment group, and the U-test according to Mann-Whi t -
ney-Wilcoxon was used to assess the changes from base­
line between the two treatment groups. 
In addition, a categorical analysis of the blood pres­
sure results in évaluable patients was also conducted, 
using the following categories of DBP response at week 
9 (six weeks of treatment) and the min imum discrimina­
tion statistic (2 I test): 1. < 9 0 m m Hg; 2. > 9 0 m m Hg, 
but with reduction > 10 m m Hg; 3. > 9 0 m m Hg, but 
with reduction < 1 0 and ^ 5 m m Hg; 4. > 9 0 m m Hg 
and with reduction < 5 m m Hg. 
RESULTS 
A total of 188 patients were recruited into the study. 
One wi thdrew during the placebo phase because of gas­
trointestinal bleeding, leaving 187 patients to be ran­
domized. Four patients discontinued the double-blind 
treatment because of adverse events. The placebo group 
comprised 90 patients (46 men, 44 women; mean age 50 
years, range 27 to 64 years), and the active t reatment 
group included 97 patients (53 men, 44 women; mean 
age 49 years, range 23 to 65 years). One hund red and ten 
patients received isradipine in the four-week selection 
phase; the remaining 77 patients h a d already received 
isradipine for periods of u p to 127 weeks before entering 
the study. 
Table 1 shows the average blood pressure values for 
the 183 patients w h o completed the double-blind study. 
The two treatment groups were comparable for both 
SBP and DBP at baseline, and both groups showed a 
statistically significant reduction in DBP after four and 
six weeks of treatment. However, the isradipine-treated 
patients showed a further fall in blood pressure between 
the fourth and sixth weeks of t reatment whereas , in the 
placebo-treated patients, there was no relevant change 
in blood pressure after the fourth week of treatment. 
The reduction in DBP from baseline was statistically 
significantly greater (P = .001) in the isradipine-treated 
patients after six weeks than in the placebo-treated pa­
tients. 
The percentage of patients achieving a supine DBP of 
90 m m Hg or less was greater (52 /96 ,54%) in the active-
treatment group than in the placebo-treated group ( 3 0 / 
87, 33%). Also greater was the number of patients w h o 
did not attain a DBP of 90 m m Hg or less, but did 
AJH-FEBRUARY 1991-VOL 4, NO. 2, PART 2 ISRADIPINE OVER 24 H O U R S 133S 
TABLE 1. AVERAGE BLOOD PRESSURE VALUES AND NORMALIZATION RATE BEFORE, DURING, AND 
AFTER TREATMENT WITH 2.5 MG ISRADIPINE OR PLACEBO TWICE DAILY 
Placebo Double-blind Phase 
Beforef After* 4 Weeks}: 6 Weeks* 
Systolic blood pressure (mm Hg) 
Isradipine 
Placebo 
Diastolic blood pressure (mm Hg) 
Isradipine 
Placebo 
Responder rate§ 
Isradipine (n = 96) 
Placebo (n = 87) 
Γ 
142 ± 12 
144 ± 14 
88 ± 6 
88 ± 6 
I 
158 ± 12 
160 ± 14 
I 
151 ±15—] 148: 
NS 
153 ± 18-
I 
153: 
102 ±5 
102 ± 5 
1 
94 ± 9 -
96 ± 8-
I 
NS 
L 
92 ± 
96 ± 
I 
14-
17-
9 -
9 -
64/96 
35/87 
(66%) 
(39%) 
f Office' blood-pressure measurement. 
f Blood pressure measured 12 h after dosage. 
§ Response = diastolic blood pressure ^ 90 mm Hg or a fall of^lO mm Hg. 
*F = .034; *** Ρ < .001; NS = not significant. 
achieve a reduction of at least 10 m m Hg in DBP [12/96 
(12%) ν 5 / 8 7 (6%)]. Thus, the total number of patients 
with either a normalization of blood pressure or a good 
blood pressure response was 6 4 / 9 6 (66%) in the isradi­
pine group and 3 5 / 8 7 (39%) in the placebo group. The 
difference in categorical response between the two 
groups was statistically significant (P = .003). 
The most common adverse event reported during the 
s tudy in both treatment groups was headache (six occur­
rences with isradipine and nine with placebo). Although 
the percentage of all patients entering the double-blind 
s tudy w h o reported adverse events was similar for both 
t reatment groups (16 /97 , 16% with isradipine and 1 3 / 
90, 14% with placebo), the total number of adverse 
events was greater in those receiving isradipine (n = 26) 
than placebo (n = 18). There were two reports of flush­
ing and three of edema in patients receiving active treat­
ment, but no reports of either in patients taking placebo. 
Four patients discontinued the double-blind treatment 
because of adverse events: one because of edema (isra­
dipine) and three because of headache (placebo). 
D I S C U S S I O N 
The blood pressure-lowering effect of isradipine under 
normal clinic conditions is well e s t ab l i shed . 1 - 5 In those 
studies, however, blood pressure was measured w h e n ­
ever the patient a t tended the clinic, and therapy was 
taken twice daily, once in the morning and again in the 
evening. Thus, the blood pressure measurements re­
flected the effects of the drug between its peak period 
and its trough. This is the blood pressure value generally 
used by physicians in their usual care of patients, but it 
does not clearly establish that the drug has a blood pres­
sure-lowering effect that persists throughout the dosing 
interval. That the effect is still present at the end of the 
12 h dosing interval has been shown in other s tudies . 6 ' 7 
Those studies were, however , either single-blind 6 or 
were carried out in elderly pat ients . 7 
The study reported here was performed to assess the 
12 h duration of action using a placebo-controlled study 
design in younger patients. The results showed a statis­
tically significantly greater lowering of DBP with isradi­
pine than with placebo. In this study, therapy was given 
at 9 PM on the evening before the next morning 's clinic 
visit, which was at 9 AM ± 30 min. Thus, the blood 
pressure values recorded were true trough values and 
the blood pressure-lowering effect was that at the end of 
the dosing interval. 
It can, therefore, be concluded that the blood pressure-
lowering effect of isradipine is present throughout the 
dosing interval and that a twice-daily regimen is appro­
priate. The fact that the blood pressure fell in the isradi­
pine-treated patients be tween the fourth and sixth 
weeks of t reatment while remaining stable, or even ris­
ing slightly, in the placebo-treated patients is further 
evidence that the reduction in blood pressure is an effect 
of the treatment and not a spontaneous change. This is 
also an indication that the effect of isradipine is not 
maximum at, for example, two weeks of t reatment and, 
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therefore, conclusions as to the magni tude and duration 
of antihypertensive effect based on studies in which the 
effects are assessed after only two weeks are of limited 
value. 
Al though the s tudy was not in tended to assess the 
tolerability of isradipine but, rather, to examine the dura­
tion of action in patients w h o h a d already shown a re­
sponse to treatment, these results also demonstra te that 
isradipine is well tolerated. Al though the number of 
adverse events (but not the number of patients report­
ing adverse events) was higher in the isradipine-treated 
patients than in the placebo-treated patients, the overall 
safety was adjudged by the investigators to be the same 
for both treatments. 
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